NCT01656343

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

Belatacept and Risk of PTLD in US Renal Transplant Recipients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 775 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

* To estimate the incidence rates of post-transplant lymphoproliferative disorder (PTLD) in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept at the time of transplantation * To estimate the incidence rates of PTLD in adult, EBV seropositive, kidney alone transplant recipients treated with calcineurin inhibitors (CNI)-based regimens at the time of transplantation * To compare the PTLD incidence rates in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept to the rates in adult, EBV seropositive, kidney alone transplant recipients treated with CNI-based regimens at the time of transplantation

Conditions

• Kidney Transplantation
• Transplantation, Kidney

Interventions

Type	Name	Description
DRUG	Calcineurin inhibitors (CNI)	No Intervention
DRUG	Belatacept	No Intervention

Timeline

• Start date: 2011-10-31
• Primary completion: 2019-08-05
• Completion: 2019-08-05
• First posted: 2012-08-03
• Last updated: 2022-07-22